ArticleCancer research2019
HDAC6 Inhibition Synergizes with Anti-PD-L1 Therapy in ARID1A-Inactivated Ovarian Cancer.
Abstract readComment
In one paragraph
Article in Cancer research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 73 papers.
0numbers the graph read from it
0cells of the map it votes in
73citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
73 citing papers in PubMed.
- Regulation of immune checkpoint molecules in cancer immune evasion and therapy.Nature reviews. Cancer · 2026Review
- Metabolic remodeling of endometriosis microenvironment: Energy stress and immune evasion.iScience · 2026Review
- Acetylation in ovarian cancer: mechanistic insights into drug resistance and emerging therapeutic opportunities.Journal of ovarian research · 2026Review
- Comprehensive molecular characterization identifies therapeutic vulnerabilities in ovarian clear cell carcinoma.Genome medicine · 2026Article
- Epigenetic modifications in cancer drug resistance: molecular mechanisms and therapeutic interventions.Molecular biomedicine · 2026Review
- Targeting miR-4653-3p/SLC25A51/SIRT3 axis to induce synthetic lethality in ARID1A-deficient colorectal cancer via blockade of DNA repair.Journal of translational medicine · 2026Article
- Small molecules targeting the PD-1/PD-L1 axis for cancer immunotherapy.Theranostics · 2026Review
- A Review of ARID1A's Role in Breast Cancer Progression: Context-Dependent Mechanisms and Therapeutic Implications.Cancers · 2025Review
- Prognostic chromatin remodeling signature stratifies survival outcomes in lung adenocarcinoma patients.Translational cancer research · 2025Article
- Epigenetic regulation in gynecological cancers: a paradigm shift in immunotherapy strategies.Journal of experimental & clinical cancer research : CR · 2025Review
- Selective Alanine Transporter Utilization Is a Therapeutic Vulnerability in ARID1A-Mutant Ovarian Cancer.Cancer research · 2025Article
- ARID1A: gene, protein, and function in endometrial cancer.Oncogene · 2025Review
- The role and mechanism of ARID1A in immunotherapy of gastric cancer.Clinical and experimental medicine · 2025Article
- Article
- A novel bispecific antibody CVL006 superior to AK112 for dual targeting of PD-L1 and VEGF in cancer therapy.Antibody therapeutics · 2025Article
- Histone deacetylase 6 and programmed death ligand-1 expressions after neoadjuvant chemotherapy are upregulated in patients with ovarian high-grade serous carcinoma.Scientific reports · 2025Article
- Clinicopathological characterization of Switch/Sucrose-non-fermentable (Swi/Snf) complex (ARID1A, SMARCA2, SMARCA4)-deficient endocervical adenocarcinoma.Cancer cell international · 2025Article
- Epithelial-mesenchymal transition orchestrates tumor microenvironment: current perceptions and challenges.Journal of translational medicine · 2025Review
- Recognition of pivotal immune genes NR1H4 and IL4R as diagnostic biomarkers in distinguishing ovarian clear cell cancer from high-grade serous cancer.Frontiers in molecular biosciences · 2025Article
- Chromatin remodeling complexes: architects influencing breast cancer progression.Frontiers in cell and developmental biology · 2025Review
13 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Comment on
Authors and funding
10 authors.
Takeshi FukumotoGene Expression and Regulation Program, The Wistar Institute, Philadelphia, Pennsylvania.
Nail FatkhutdinovGene Expression and Regulation Program, The Wistar Institute, Philadelphia, Pennsylvania.
Joseph A ZundellGene Expression and Regulation Program, The Wistar Institute, Philadelphia, Pennsylvania.
Evgenii N TcyganovImmunology, Microenvironment & Metastasis Program, The Wistar Institute, Philadelphia, Pennsylvania.ORCID 0000-0001-8605-7291
Timothy NacarelliGene Expression and Regulation Program, The Wistar Institute, Philadelphia, Pennsylvania.
Sergey KarakashevGene Expression and Regulation Program, The Wistar Institute, Philadelphia, Pennsylvania.
Shuai WuGene Expression and Regulation Program, The Wistar Institute, Philadelphia, Pennsylvania.ORCID 0000-0002-3183-5081
Qin LiuMolecular and Cellular Oncogenesis Program, The Wistar Institute, Philadelphia, Pennsylvania.ORCID 0000-0001-9964-580X
Dmitry I GabrilovichImmunology, Microenvironment & Metastasis Program, The Wistar Institute, Philadelphia, Pennsylvania.
Rugang ZhangGene Expression and Regulation Program, The Wistar Institute, Philadelphia, Pennsylvania. rzhang@wistar.org.ORCID 0000-0002-7255-2360
Funding
Tumor Microenvironment and MetastasisP30CA010815 · NCI · WISTAR INSTITUTE · PI Luis J Montaner · 1985 to 2026
$75.9MTargeting the MAP and PI3 Kinase Pathways in MelanomaP01CA114046 · NCI · WISTAR INSTITUTE · PI MURPHY, MAUREEN E. · 2008 to 2023
$37.1MSPORE in Ovarian CancerP50CA228991 · NCI · JOHNS HOPKINS UNIVERSITY · PI Ronny I DRAPKIN, IE-MING SHIH · 2018 to 2026
$20.5MTRAINING PROGRAM IN BASIC CANCER RESEARCHT32CA009171 · NCI · WISTAR INSTITUTE · PI Alessandro Gardini · 1985 to 2026
$15.3MMechanistic basis and therapeutic strategies for ARID1A mutation in ovarian cancerR01CA202919 · NCI · WISTAR INSTITUTE · PI Xi Chen, Rugang Zhang · 2016 to 2026
$4.1MRole of BRCA1 Pathway in Regulating Oncogene-Induced SenescenceR01CA160331 · NCI · WISTAR INSTITUTE · PI ZHANG, RUGANG · 2012 to 2021
$4.0MTargeting EZH2 in CARM1-expressing epithelial ovarian cancerR01CA163377 · NCI · WISTAR INSTITUTE · PI ZHANG, RUGANG · 2012 to 2021
$3.7MSynthetic lethality based combination approaches to ARID1A mutation in ovarian cancerR01CA239128 · NCI · WISTAR INSTITUTE · PI ZHANG, RUGANG · 2019 to 2024
$2.5MNCI NIH HHS P01 CA114046NCI NIH HHS P30 CA010815NCI NIH HHS P50 CA228991NCI NIH HHS R01 CA160331NCI NIH HHS R01 CA163377NCI NIH HHS R01 CA202919NCI NIH HHS R01 CA239128NCI NIH HHS T32 CA009171
Abstract
PubMed holds no abstract for this paper.
Indexed as
Adenocarcinoma, Clear CellOvarian NeoplasmsAnimalsB7-H1 AntigenCD8-Positive T-LymphocytesDNA-Binding ProteinsFemaleHistone Deacetylase 6HumansMiceNuclear ProteinsTranscription FactorsTumor MicroenvironmentARID1A protein, humanArid1a protein, mouseB7-H1 AntigenDNA-Binding ProteinsHDAC6 protein, humanHistone Deacetylase 6Nuclear ProteinsTranscription Factors
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.